What happened with HRTX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Heron Therapeutics sells medicines that help patients manage the effects of chemotherapy and surgery. Most product revenue comes from oncology: CINVANTI and SUSTOL are used with other medicines to prevent chemotherapy-related nausea and vomiting. A limited number of specialty distributors and full-line wholesalers buy Heron’s medicines and resell them to healthcare providers and hospitals.
Its acute-care business sells ZYNRELEF to manage pain after specified surgical procedures and APONVIE to prevent postoperative nausea and vomiting. Crosslink Network is Heron’s exclusive U.S. co-promoter for ZYNRELEF, and Heron pays it agreed compensation.
Sales depend on healthcare providers choosing these medicines and government and private insurers providing adequate coverage and reimbursement. Heron has no manufacturing facilities of its own; it relies on a small number of contract manufacturers and single suppliers for some critical materials. Its products are approved for sale only in the United States, and it cannot promote them for uses outside their approved indications.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Watch hospital adoption and reimbursement of Heron's ZYNRELEF and APONVIE, plus pricing and market share for its drugs that prevent chemotherapy-related nausea and vomiting: these matter more to its results than the supplied candidates' businesses.
Heron Therapeutics, Inc. earningsThis company
Heron Therapeutics’ report will show whether growth in acute-care products ZYNRELEF and APONVIE can offset pressure on oncology sales.
Watch acute-care and oncology product sales alongside cost of product sales as a share of revenue. Continued acute-care growth, steadier oncology sales and a stable cost share would show that demand for newer products is broadening without being offset by oncology weakness or supply costs. Slower acute-care growth, further oncology declines or a rising cost share would show that growth remains narrow and product economics are under more pressure.
